Cargando…
Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study
BACKGROUND: Pre-diabetes is a condition in which blood glucose levels are high but not as high as in diabetic patients. However, it can lead to diabetes, making it a serious global health issue. Previous studies have shown that the gut microbiome can affect insulin sensitivity and improve glucose ma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084663/ https://www.ncbi.nlm.nih.gov/pubmed/37038214 http://dx.doi.org/10.1186/s13098-023-01050-9 |
_version_ | 1785021786787676160 |
---|---|
author | AkbariRad, Mina Shariatmaghani, Somayeh Sadat Razavi, Bibi Marjan Majd, Hassan Mehrad Shakhsemampour, Zeinab Sarabi, Mehrdad Jafari, Maryam Azarkar, Setareh Ghalibaf, AmirAli Moodi Khorasani, Zahra Mazloum |
author_facet | AkbariRad, Mina Shariatmaghani, Somayeh Sadat Razavi, Bibi Marjan Majd, Hassan Mehrad Shakhsemampour, Zeinab Sarabi, Mehrdad Jafari, Maryam Azarkar, Setareh Ghalibaf, AmirAli Moodi Khorasani, Zahra Mazloum |
author_sort | AkbariRad, Mina |
collection | PubMed |
description | BACKGROUND: Pre-diabetes is a condition in which blood glucose levels are high but not as high as in diabetic patients. However, it can lead to diabetes, making it a serious global health issue. Previous studies have shown that the gut microbiome can affect insulin sensitivity and improve glucose management, which can reduce or delay the progression of pre-diabetes to type 2 diabetes mellitus. This study was designed to investigate the effects of probiotics on glycemic and lipid profile control in pre-diabetic patients. METHODS: This randomized, double-blinded clinical trial was conducted on 70 pre-diabetic patients at the Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Participants were divided into two groups, both of which received lifestyle modification training. One of the groups also received 500 mg/day probiotic capsules for three months, while the other group received a placebo. Before and after the three-month period, systolic and diastolic blood pressure, serum insulin level, hemoglobin A1c (HbA1c), fasting blood sugar (FBS), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) were measured and compared using statistical tests to examine the effect of probiotics. RESULTS: A total of 70 individuals participated in the trial, including 50 women (71.4%) and 20 men (28.6%), with an average age of 43.53 ± 8.54 years. At the end of the trial, the mean weight (P < 0.001), FBS (P < 0.001), HbA1c (P = 0.035), TG (P = 0.004), and LDL (P = 0.016) were significantly reduced in the intervention group, while their insulin level (P = 0.041) and HDL (P = 0.001) were significantly increased. However, mean systolic (P = 0.459) and diastolic blood pressure (P = 0.961) and insulin resistance (P = 0.235) did not show any significant difference in the intervention group from the beginning of the study. CONCLUSION: Our study showed that probiotic administration is effective in improving the glucose and lipid profile of pre-diabetic patients. However, it was not significantly different from the placebo. |
format | Online Article Text |
id | pubmed-10084663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100846632023-04-11 Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study AkbariRad, Mina Shariatmaghani, Somayeh Sadat Razavi, Bibi Marjan Majd, Hassan Mehrad Shakhsemampour, Zeinab Sarabi, Mehrdad Jafari, Maryam Azarkar, Setareh Ghalibaf, AmirAli Moodi Khorasani, Zahra Mazloum Diabetol Metab Syndr Research BACKGROUND: Pre-diabetes is a condition in which blood glucose levels are high but not as high as in diabetic patients. However, it can lead to diabetes, making it a serious global health issue. Previous studies have shown that the gut microbiome can affect insulin sensitivity and improve glucose management, which can reduce or delay the progression of pre-diabetes to type 2 diabetes mellitus. This study was designed to investigate the effects of probiotics on glycemic and lipid profile control in pre-diabetic patients. METHODS: This randomized, double-blinded clinical trial was conducted on 70 pre-diabetic patients at the Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Participants were divided into two groups, both of which received lifestyle modification training. One of the groups also received 500 mg/day probiotic capsules for three months, while the other group received a placebo. Before and after the three-month period, systolic and diastolic blood pressure, serum insulin level, hemoglobin A1c (HbA1c), fasting blood sugar (FBS), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) were measured and compared using statistical tests to examine the effect of probiotics. RESULTS: A total of 70 individuals participated in the trial, including 50 women (71.4%) and 20 men (28.6%), with an average age of 43.53 ± 8.54 years. At the end of the trial, the mean weight (P < 0.001), FBS (P < 0.001), HbA1c (P = 0.035), TG (P = 0.004), and LDL (P = 0.016) were significantly reduced in the intervention group, while their insulin level (P = 0.041) and HDL (P = 0.001) were significantly increased. However, mean systolic (P = 0.459) and diastolic blood pressure (P = 0.961) and insulin resistance (P = 0.235) did not show any significant difference in the intervention group from the beginning of the study. CONCLUSION: Our study showed that probiotic administration is effective in improving the glucose and lipid profile of pre-diabetic patients. However, it was not significantly different from the placebo. BioMed Central 2023-04-10 /pmc/articles/PMC10084663/ /pubmed/37038214 http://dx.doi.org/10.1186/s13098-023-01050-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research AkbariRad, Mina Shariatmaghani, Somayeh Sadat Razavi, Bibi Marjan Majd, Hassan Mehrad Shakhsemampour, Zeinab Sarabi, Mehrdad Jafari, Maryam Azarkar, Setareh Ghalibaf, AmirAli Moodi Khorasani, Zahra Mazloum Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
title | Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
title_full | Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
title_fullStr | Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
title_full_unstemmed | Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
title_short | Probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
title_sort | probiotics for glycemic and lipid profile control of the pre-diabetic patients: a randomized, double-blinded, placebo-controlled clinical trial study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084663/ https://www.ncbi.nlm.nih.gov/pubmed/37038214 http://dx.doi.org/10.1186/s13098-023-01050-9 |
work_keys_str_mv | AT akbariradmina probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT shariatmaghanisomayehsadat probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT razavibibimarjan probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT majdhassanmehrad probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT shakhsemampourzeinab probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT sarabimehrdad probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT jafarimaryam probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT azarkarsetareh probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT ghalibafamiralimoodi probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy AT khorasanizahramazloum probioticsforglycemicandlipidprofilecontroloftheprediabeticpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrialstudy |